About 64 results
Open links in new tab
  1. Recursion's Drug Discovery Pipeline | Recursion

    Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets. We focus on indications with high unmet need, …

  2. Pioneering AI Drug Discovery | Recursion

    All of our results feed back into our drug discovery and drug development platform – the Recursion Operating System – in a continuously improving feedback loop.

  3. Recursion Pharmaceuticals, Inc. - Recursion and Exscientia Enter ...

    Aug 8, 2024 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San …

  4. Recursion Reports Third Quarter 2025 Financial Results and Provides ...

    Oct 9, 2025 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, …

  5. 28th Annual Needham Growth Conference - ir.recursion.com

    The Investor Relations website contains information about Recursion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

  6. Recursion Reports Second Quarter 2025 Financial Results and Provides ...

    Jun 30, 2025 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, …

  7. David Hallett, Ph.D. - recursion.com

    Dave Hallett comes to Recursion after approximately 5 years as the Chief Scientific Officer and Interim CEO of Exscientia. David Hallett, Ph.D., is an experienced “drug hunter” with over 20 years’ track …

  8. ir.recursion.com

    ir.recursion.com

  9. Matchmaker - portfolio.recursion.com

    Dive into an interactive experience with our pipeline, partners and models.

  10. Recursion Reports First Quarter 2025 Financial Results and Provides ...

    Mar 31, 2025 · In total, the partnership has generated $130 million of cash inflows (including an upfront payment) to Recursion to date. Recursion’s collaboration within Neuroscience and a GI Oncology …